CORPORATE PRESENTATION NASDAQ COMMON: XOMA NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO THE ROYALTY AGGREGATOR FOR BIOTECH COMPANIES Q1 2026 DISCLAIMERS Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future potential monetization opportunities, active transactions with significant financial implications, collaborations poised for s ...

Summary of Compugen Conference Call Company Overview - **Company**: Compugen - **CEO**: Eran Ophir - **Industry**: Biotechnology, specifically focused on immuno-oncology Key Topics Discussed 1. TIGIT Bispecific Antibody - Rovagacimatib - **Partnership**: Licensed to AstraZeneca - **Clinical Trials**: AstraZeneca is conducting 11 Phase 3 trials with rovagacimatib, with some trials using it as a backbone without direct comparison to PD-1 inhibitors [4][5] - **Trial Design**: AstraZeneca's approach includes novel combinations and specific patient populations, which may improve the chances of success compared to previous trials by other companies [10][11][12] - **Efficacy**: The bispecific format of the antibody is believed to provide cooperative binding, potentially leading to better efficacy than traditional PD-1 and TIGIT combinations [10][20] - **Market Position**: Rovagacimatib may become the last TIGIT antagonist standing in the clinic, as competitors have faced failures [3][9] 2. PVRIG Antagonist - COM701 - **Clinical Program**: Ongoing trial called MAIA for platinum-sensitive ovarian cancer patients [60] - **Trial Design**: The study is randomized with 40 patients receiving COM701 and 20 receiving placebo, focusing on monotherapy activity [62][68] - **Biological Rationale**: PVRIG is expressed on stem-like memory T cells, which may drive T cell proliferation in tumors, particularly in less inflamed environments like ovarian cancer [63][64] - **Expected Outcomes**: Aiming for a clinically meaningful improvement in progression-free survival (PFS) of at least 3 months compared to historical controls [70][71] 3. IL-18 Binding Protein Program - **Partnership**: Licensed to Gilead - **Clinical Trials**: First patient dosed in early 2025, focusing on monotherapy and combination with Gilead's PD-1 inhibitor [80] - **Mechanism**: The program aims to block IL-18 binding protein to activate IL-18, which is crucial for immune response in the tumor microenvironment [81][82] Additional Insights - **Market Strategy**: Compugen is focusing on specific patient populations and innovative trial designs to enhance the probability of success in clinical trials [11][12][46] - **AI Utilization**: The company employs AI in its computational platform, Unigen, to analyze tumor microenvironments and identify new therapeutic targets [85][86] - **Future Directions**: Compugen is exploring new biologies and mechanisms of action in oncology, with plans to report on new targets as they progress [87][88] Conclusion Compugen is strategically positioned in the biotechnology sector with promising clinical programs in immuno-oncology. The focus on innovative trial designs, specific patient populations, and the use of advanced technologies like AI may enhance the likelihood of successful outcomes in their ongoing and future clinical trials.

Financial Data and Key Metrics Changes - The company reported approximately $67.3 million in revenues for Q4 2025 and approximately $72.8 million for the full year 2025, compared to approximately $1.5 million and $27.9 million for the same periods in 2024, reflecting significant growth due to the $65 million upfront payment from AstraZeneca and other milestone payments [17][18] - R&D expenses for Q4 2025 were approximately $5.5 million, down from $5.9 million in Q4 2024, while total R&D expenses for the year were approximately $22.8 million, compared to $24.8 million in 2024, indicating a decrease primarily due to winding down prior clinical trials [18] - The company reported a net profit of approximately $56.8 million for Q4 2025, or approximately $0.60 per share, compared to a net loss of approximately $6.1 million in Q4 2024 [19] Business Line Data and Key Metrics Changes - The company advanced its clinical programs, initiating new trials for COM-701 and GS-0321, with COM-701 showing promising results in the MAIA-ovarian trial [5][10] - The partnership with Gilead for GS-0321 includes potential future milestones of up to $758 million, indicating strong collaboration and financial prospects [12] Market Data and Key Metrics Changes - The company extended its cash runway into 2029, supported by a non-dilutive transaction with AstraZeneca, which is crucial for funding ongoing and future clinical trials [4][16] - AstraZeneca's rilvegostomig is involved in a broad late-stage development program with an estimated peak annual revenue potential of over $5 billion, highlighting the market potential of the company's assets [8] Company Strategy and Development Direction - The company aims to continue executing its MAIA-ovarian adaptive trial and expand its clinical development plan across ovarian cancer and other indications [10][14] - The leadership transition to a new CEO is expected to provide operational focus and strategic continuity, positioning the company for its next phase of growth [4][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for COM-701 to address significant unmet medical needs in ovarian cancer [10][33] - The company remains committed to leveraging its computational drug target discovery engine to deliver innovative immune oncology assets, supported by a solid financial outlook [14][15] Other Important Information - The company has diversified its leadership team and is focused on advancing its early-stage pipeline, which is managed by a large team [4][14] - The company retains the majority of its royalty interest in rilvegostomig, ensuring that its economic interests remain intact despite the recent monetization deal [6][7] Q&A Session Summary Question: What to expect in the 1Q 2027 update with COM-701? - Management indicated that the current trial is an adaptive design, and data maturation is expected in Q1 2027, with the timeline for registration depending on the totality of the data [23][24] Question: Cadence of potential milestones for rilvegostomig? - The next milestone payment is expected upon BLA acceptance, which will trigger an additional $25 million payment, with a total of $195 million in future milestones from AstraZeneca [27][28] Question: Shift in interim analysis timing for the ovarian trial? - The shift to Q1 2027 was due to slower opening of major academic sites, but all sites are now open, and the trial is on track [32][34] Question: Discussions on expanding the use of COM-902 derived TIGIT? - Management noted that AstraZeneca controls rilvegostomig and is expanding its use, but discussions on COM-902 are separate as the company fully owns it [35] Question: Data expectations for GS-0321? - Data reporting will align with Gilead's guidelines, typically presented at scientific conferences, including activity and safety data [36]

Financial Data and Key Metrics Changes - The company reported approximately $67.3 million in revenues for Q4 2025 and approximately $72.8 million for the full year 2025, compared to approximately $1.5 million and $27.9 million for the same periods in 2024, indicating significant growth [17][18] - Net profit for Q4 2025 was approximately $56.8 million or approximately $0.60 per share, compared to a net loss of approximately $6.1 million or approximately $0.07 per share in Q4 2024 [19] - For the full year 2025, net profit was approximately $35.3 million or approximately $0.38 per share, compared to a net loss of approximately $14.2 million or approximately $0.16 per share in 2024 [20] Business Line Data and Key Metrics Changes - The company advanced its clinical programs, initiating new trials for COM-701 and GS-0321, with significant updates presented at major conferences [5][10] - The MAIA-ovarian trial for COM-701 has expanded its footprint globally, with sites opened in the U.S., France, and Israel [9] Market Data and Key Metrics Changes - The partnership with AstraZeneca has been strengthened through a transaction that added $65 million in upfront non-dilutive capital, extending the cash runway into 2029 [6][16] - The company retains the majority of its royalty interest in rilvegostomig, which is projected to have a peak annual revenue potential of over $5 billion [8] Company Strategy and Development Direction - The company aims to continue executing its clinical trials, particularly the MAIA-ovarian trial, and is focused on advancing its early-stage pipeline [10][14] - The leadership transition to a new CEO is expected to provide operational focus and strategic continuity for the company's growth [4][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiation of their products and the strategic execution of clinical trials, particularly in the context of the competitive landscape [12][13] - The company is committed to leveraging its computational drug target discovery engine to deliver innovative immune oncology assets [14] Other Important Information - The company has a solid balance sheet with approximately $145.6 million in cash equivalents as of December 31, 2025, which will support its operational plans into 2029 [16] - The company is eligible for up to $758 million in future milestones and tiered royalties from its partnership with Gilead [11] Q&A Session Summary Question: What to expect in the 1Q 2027 update with COM-701? - Management indicated that the current trial is an adaptive design and anticipates data maturation in 1Q 2027, with the timeline for registration depending on the totality of the data [23][24] Question: Cadence of potential outlying milestones for rilvegostomig? - The next milestone is BLA acceptance, which will trigger an additional $25 million payment, with a total of $195 million in milestones remaining from AstraZeneca [27][28] Question: Reason for the shift in interim analysis timing for the ovarian trial? - The shift to Q1 2027 was due to slower opening of major academic sites, but all sites are now open and on track for the readout [32][34] Question: Discussions on expanding the use of COM-902 derived TIGIT? - Management noted that AstraZeneca is expanding rilvegostomig but did not discuss specific plans for COM-902 [35] Question: Data expectations for GS-0321? - Data reporting will align with Gilead's guidelines, typically presented at scientific conferences, including activity and safety [36]

Financial Data and Key Metrics Changes - The company reported approximately $67.3 million in revenues for Q4 2025 and approximately $72.8 million for the full year 2025, compared to approximately $1.5 million and $27.9 million for the same periods in 2024, reflecting significant growth [17][18] - Net profit for Q4 2025 was approximately $56.8 million or approximately $0.60 per share, compared to a net loss of approximately $6.1 million or approximately $0.07 per share in Q4 2024 [19] - For the full year 2025, net profit was approximately $35.3 million or approximately $0.38 per share, compared to a net loss of approximately $14.2 million or approximately $0.16 per share in 2024 [20] Business Line Data and Key Metrics Changes - The company advanced its clinical programs, initiating new trials for COM-701 and GS-0321, with significant updates presented at major conferences [5][9] - The partnership with Gilead for GS-0321 includes potential future milestones of up to $758 million and tiered royalties [11] Market Data and Key Metrics Changes - The company extended its cash runway into 2029, assuming no further cash inflows, due to a non-dilutive transaction with AstraZeneca [4][6] - AstraZeneca's rilvegostomig is involved in a broad late-stage development program with an estimated peak annual revenue potential of over $5 billion [7] Company Strategy and Development Direction - The company aims to continue executing its MAIA-ovarian adaptive trial and expand its clinical development plan across ovarian cancer and other indications [9][10] - The leadership transition to a new CEO is expected to provide operational focus and strategic continuity for the company's growth [4][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiation of their products and the strategic execution of their clinical trials, particularly in the context of the competitive landscape [12][13] - The company remains committed to investing in its early-stage pipeline and leveraging its computational drug target discovery engine [13] Other Important Information - The company has a solid balance sheet with approximately $145.6 million in cash equivalents as of December 31, 2025 [16] - The company is focused on maintaining a favorable safety profile for its products while advancing innovative immune oncology therapies [12] Q&A Session Summary Question: Expectations for the 1Q 2027 update with COM-701 - Management indicated that data maturation is expected in 1Q 2027, with the timeline for registration dependent on the totality of the data [22][23] Question: Cadence of potential milestones for rilvegostomig - The next milestone payment of $25 million is expected upon BLA acceptance, with total remaining milestones up to $195 million [26][27] Question: Shift in interim analysis timing for the ovarian trial - The shift to Q1 2027 was due to slower opening of major academic sites, which are now all operational [30][31] Question: Discussions on expanding the use of COM-902 derived TIGIT - The company clarified that AstraZeneca controls rilvegostomig and is expanding its use, but discussions on COM-902 are separate [33] Question: Data reporting for GS-0321 - Data reporting will align with Gilead's guidelines, typically presented at scientific conferences, including activity and safety [34]

Core Insights - Compugen Ltd. reported significant progress in 2025, including a non-dilutive monetization agreement with AstraZeneca that extends its cash runway into 2029, enhancing its financial stability and preserving the potential value of its assets [2][4]. Financial Highlights - As of December 31, 2025, Compugen had approximately $145.6 million in cash and equivalents, bolstered by a $65 million upfront payment from AstraZeneca for royalty monetization [3][4]. - Revenues for Q4 2025 were approximately $67.3 million, and for the full year, revenues reached approximately $72.8 million, a significant increase from $27.9 million in 2024 [4][6]. - The company reported a net profit of approximately $56.8 million for Q4 2025, translating to about $0.60 per share, compared to a net loss of approximately $6.1 million in Q4 2024 [10][15]. Clinical Development and Pipeline - Compugen initiated new clinical trials for COM701 (MAIA-ovarian) and GS-0321 in 2025, expanding its clinical footprint across the U.S., Israel, and France [2][4]. - The company is on track for an interim analysis of the MAIA-ovarian trial in Q1 2027, with promising data presented at ESMO 2025 [4][10]. - Compugen continues to invest in early-stage discovery programs targeting undisclosed drug candidates, leveraging its AI/ML-powered computational discovery platform [2][12]. Strategic Partnerships - The partnership with AstraZeneca includes potential milestone payments of up to $1 billion, in addition to future royalties, which positions Compugen for long-term financial success [2][4][5]. - Gilead is collaborating with Compugen on the GS-0321 program, further diversifying the company's pipeline and revenue potential [2][12].

Summary of Compugen's Conference Call Company Overview - **Company**: Compugen (Ticker: CGEN) - **Industry**: Biotechnology, specifically focused on oncology and immunotherapy Key Points Discussed Pipeline and Development Focus - Compugen is focusing on its pipeline assets, particularly **COM701**, which targets the **PVRIG** pathway, a novel checkpoint with distinct biology compared to PD-1 and TIGIT [4][5] - The rationale for targeting PVRIG is its dominance in ovarian cancer, which is a less inflamed tumor type, making it a challenging indication [4] - Clinical studies have shown that **COM701** can elicit responses in patients with platinum-resistant ovarian cancer, particularly those who are PD-1 negative [5][6] Clinical Trial Insights - The company is conducting a randomized study (MAIA) with **60 patients** who are platinum-sensitive, comparing **COM701** monotherapy to placebo [10] - Historical control data suggests a progression-free survival (PFS) of **5.5 months**, with Compugen aiming to extend this by **3 months** with COM701 [11] - In the last line of treatment, **40%** of patients showed clinical benefit with a durable PFS of **10.5 months** [10] Market Opportunity and Unmet Need - There is a significant unmet need in earlier lines of treatment for platinum-sensitive ovarian cancer patients, which COM701 aims to address [7] - The potential market opportunity for COM701 is substantial, given the lack of standard care in this patient population [7] Competitive Landscape - Compugen is the first to move PVRIG into clinical trials, with some early programs from other companies also exploring this target [21] - The discussion highlighted the differentiation of Compugen's approach from other candidates in the TIGIT space, particularly focusing on the safety profile of their Fc-reduced format compared to Fc-active formats that have faced challenges [23][24] Financial Aspects - Compugen has a partnership with **AstraZeneca** for **rilvegostomig**, with potential milestones totaling **$195 million** and mid-single-digit tiered royalties [36][38] - The company has also monetized a portion of future royalties, receiving **$65 million** upfront, which supports ongoing development [38] Other Assets and Collaborations - Compugen is also developing **GS-0321**, an antibody against the IL-18 binding protein in collaboration with **Gilead**, which is currently in phase one trials [39][40] - The structure of the deal with Gilead includes **$60 million** upfront and potential milestones of **$758 million** along with low double-digit royalties [48] Future Outlook - Compugen is exploring new biological targets and plans to continue leveraging its AI-based computational engine for future developments [49][50] - The company is cautious about providing timelines for new announcements, emphasizing the need for validation before committing to guidelines [50] Industry Context - The call addressed the recent disappointments in the TIGIT space, particularly referencing **Arcus** and their failed trials, while highlighting how Compugen's strategies differ [52][53] - AstraZeneca's ongoing studies and their approach to combining rilvegostomig with other therapies were discussed as a promising avenue for success [30][31] Conclusion - Compugen is positioned to address significant unmet needs in oncology, particularly in ovarian cancer, with a strong pipeline and strategic partnerships that could lead to substantial market opportunities in the future.

Core Insights - Compugen Ltd. is a clinical-stage cancer immunotherapy company that utilizes AI/ML for drug target discovery [1] - The company will participate in two upcoming investor conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Partners 2026 Global Healthcare Conference [1] Company Overview - Compugen is focused on developing cancer immunotherapies through its AI/ML powered computational discovery platform, Unigen™ [1] - The company has two main programs targeting TIGIT: COM902, a fully owned anti-TIGIT antibody in Phase 1, and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca [1] - Additional programs include COM701, a potential first-in-class anti-PVRIG antibody, and GS-0321, a high affinity anti-IL-18 binding protein antibody licensed to Gilead [1] Upcoming Events - The Oppenheimer conference will take place on February 26, 2026, featuring a fireside chat at 2 PM ET [1] - The Leerink Partners conference is scheduled for March 9, 2026, with a fireside chat at 8:40 AM ET [1] - Live webcasts of the fireside chats will be available on Compugen's Investor Relations website [1]

Core Viewpoint - Compugen has appointed Michele Holcomb, Ph.D., as an independent director to its Board of Directors, effective February 11, 2026, bringing over 30 years of experience in biotech, pharmaceuticals, and healthcare services [1] Group 1: Appointment Details - Michele Holcomb's extensive background includes strategic insights, corporate development, and operational experience, which will enhance Compugen's Board [1] - The appointment is expected to strengthen the company's ability to convert clinical opportunities into long-term value for patients and shareholders [1] Group 2: Company Overview - Compugen is a clinical-stage cancer immunotherapy company utilizing AI/ML for drug target discovery [1] - The company has multiple first-in-class clinical programs and partnerships, including two validating pharma partnerships [1] - Compugen's pipeline includes several differentiated programs targeting TIGIT and other novel drug targets [1] Group 3: Dr. Holcomb's Background - Dr. Holcomb has held significant roles, including EVP at Cardinal Health and COO at Teva Pharmaceuticals, focusing on strategy and business development [1] - She has experience in managing partnerships, acquisitions, and optimizing portfolios in the healthcare sector [1] - Dr. Holcomb serves on various boards and has a strong academic background with a BS and PhD in chemistry [1]

Core Insights - Compugen Ltd. has entered into a strategic agreement with AstraZeneca to monetize a portion of its future royalties from rilvegostomig, aimed at strengthening its financial position and advancing its immuno-oncology pipeline [1][3] Financial Highlights - The agreement includes an upfront payment of $65 million and a potential additional $25 million upon reaching the next milestone related to the Biologics License Application (BLA) acceptance [5][6] - Compugen retains the majority of its future royalties and is eligible for tiered royalties of up to mid-single digits on future sales, along with potential regulatory and commercial milestones totaling up to $195 million [6] Product Development - Rilvegostomig is a first-in-class dual-checkpoint bispecific antibody that targets PD-1 and TIGIT, currently in Phase 3 development by AstraZeneca [6] - Compugen's pipeline includes two differentiated Fc-reduced programs targeting TIGIT: COM902, in Phase 1 development, and rilvegostomig, with the TIGIT component derived from COM902 [4][6] - The company also has COM701, a potential first-in-class anti-PVRIG antibody, and GS-0321, a high affinity anti-IL-18 binding protein antibody licensed to Gilead [4] Strategic Implications - This non-dilutive transaction is expected to extend Compugen's cash runway into 2029, allowing the company to continue advancing its innovative immuno-oncology pipeline [3][5] - The agreement reflects Compugen's belief in the significant long-term upside potential of rilvegostomig, which is seen as a key value driver for the company and its shareholders [3][5]